Valuation: BICYCL

Market Cap 27Cr 23Cr 22Cr 20Cr 38Cr 2.58TCr 39Cr 258.34Cr 101.13Cr 1.28TCr 101.46Cr 99Cr 4.25TCr P/E 2026 *
-1.45x
P/E 2027 * -1.68x
Enterprise Value -18Cr -16Cr -15Cr -13Cr -25Cr -1.73TCr -26Cr -173.13Cr -68Cr -860.31Cr -68Cr -66Cr -2.85TCr EV / Sales 2026 *
-11.1x
EV / Sales 2027 * -20.3x
Free-Float
71.44%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 57 01/09/2015
Director of Finance/CFO 46 29/01/2026
Chief Tech/Sci/R&D Officer - 01/06/2025
Director TitleAgeSince
Director/Board Member 57 01/09/2015
Director/Board Member 63 17/03/2021
Director/Board Member 69 20/02/2024
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 27Cr
+0.05%+2.80%+38.17%+74.12% 5.65TCr
-3.06%-10.22%+23.62%+58.59% 5.36TCr
+1.84%+3.27%-14.06%-12.13% 2.29TCr
-0.15%-7.92%-9.42%+352.23% 2.14TCr
+0.15%-0.77%+23.76%-11.52% 2.03TCr
-0.67%-1.73%+33.09%-31.09% 1.76TCr
-1.45%-7.24%+17.67%+563.14% 1.47TCr
+9.91%+2.64%+188.84%+326.19% 1.35TCr
+3.83%-0.56%+47.77%+170.70% 1.33TCr
Average +1.04%-1.88%+38.83%+165.58% 2.6TCr
Weighted average by Cap. +0.14%-1.70%+31.71%+123.13%

Financials

2026 *2027 *
Net sales 1.63Cr 1.42Cr 1.32Cr 1.21Cr 2.29Cr 155.51Cr 2.33Cr 16Cr 6.11Cr 78Cr 6.13Cr 5.99Cr 256.62Cr 66.89L 58.12L 54.18L 49.8L 93.93L 64Cr 95.57L 6.4Cr 2.5Cr 32Cr 2.51Cr 2.46Cr 105.22Cr
Net income -19Cr -16Cr -15Cr -14Cr -26Cr -1.77TCr -27Cr -177.77Cr -70Cr -883.39Cr -70Cr -68Cr -2.92TCr -17Cr -15Cr -14Cr -13Cr -24Cr -1.64TCr -25Cr -164.7Cr -64Cr -818.44Cr -65Cr -63Cr -2.71TCr
Net Debt -45Cr -39Cr -37Cr -34Cr -63Cr -4.3TCr -64Cr -431.47Cr -168.9Cr -2.14TCr -169.45Cr -165.71Cr -7.1TCr -41Cr -35Cr -33Cr -30Cr -57Cr -3.87TCr -58Cr -388.08Cr -151.92Cr -1.93TCr -152.41Cr -149.05Cr -6.38TCr
Logo BICYCL
Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing a class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The Company is evaluating zelenectide pevedotin, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-